XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Total
LINICO
Common Stock
Additional Paid in Capital
Additional Paid in Capital
LINICO
Accumulated Deficit
Treasury Stock
Non-Controlling Interest
Non-Controlling Interest
LINICO
Beginning balance (in shares) at Dec. 31, 2021     71,207,832            
Beginning balance at Dec. 31, 2021 $ 92,970,522   $ 47,065 $ 338,936,145   $ (245,542,688) $ (3,870,000) $ 3,400,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Common stock received and cancelled in the rescission of the LPB transaction (in shares)     (3,500,000)            
Common stock received and cancelled in the rescission of the LPB transaction (5,110,000)   $ (2,331) (5,107,669)          
Common stock issuance costs (70,000)     (70,000)          
Capital contribution to LINICO by Aqua Metals   $ 500,000     $ 176,695       $ 323,305
Employee and director share-based compensation 108,599   $ 119 108,480          
Sales of treasury shares (1,485 common shares) 2,721     805     1,916    
Net loss (6,547,023)         (6,378,555)   (168,468)  
Ending balance (in shares) at Mar. 31, 2022     67,707,832            
Ending balance at Mar. 31, 2022 81,854,819   $ 44,853 334,044,456   (251,921,243) (3,868,084) 3,554,837  
Beginning balance (in shares) at Dec. 31, 2021     71,207,832            
Beginning balance at Dec. 31, 2021 92,970,522   $ 47,065 338,936,145   (245,542,688) (3,870,000) 3,400,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Sales of treasury shares (1,485 common shares) $ 240,077                
Ending balance (in shares) at Dec. 31, 2022 91,442,018   91,442,018            
Ending balance at Dec. 31, 2022 $ 56,363,459   $ 60,660 348,390,556   (291,491,432) (3,360,867) 2,764,542  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock (in shares)     6,090,276            
Issuance of common stock 2,150,000   $ 4,056 2,145,944          
Common stock issuance costs (607,620)     (607,620)          
Issuance of common shares for stock issuance costs (in shares)     963,445            
Issuance of common stock for stock issuance costs 350,000   $ 642 349,358          
Issuance of common stock for conversion of debt and accrued interest (in shares)     4,539,413            
Issuance of common stock for conversion of debt and accrued interest 1,662,723   $ 3,023 1,659,700          
Employee and director share-based compensation 126,288   $ 120 126,168          
LINICO dividends earned by AQMS not distributed   $ (44,703)             $ (44,703)
Net loss $ (5,681,742)         (5,668,937)   (12,805)  
Ending balance (in shares) at Mar. 31, 2023 103,035,152   103,035,152            
Ending balance at Mar. 31, 2023 $ 54,318,405   $ 68,501 $ 352,064,106   $ (297,160,369) $ (3,360,867) $ 2,707,034